title: Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.
abstract: Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Khera.Nandita@mayo.edu.
authors.forename: Nandita
authors.initials: N
authors.lastname: Khera
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Amy
authors.initials: A
authors.lastname: Emmert
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Barry E
authors.initials: BE
authors.lastname: Storer
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Sandmaier
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Lee
mesh_terms: D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000191:economics / Q000473:pathology; D019337:Hematologic Neoplasms / Q000191:economics* / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000191:economics*
keywords: Allogeneic transplantation; Costs; Economics; Hematopoietic stem cell transplantation